



Disease subset	Status of disease, treatment phase	MoAb, treatment program	Clinical studies
Burkitt leukemia/lymphoma	Frontline therapy	Rituximab (CD20) plus chemotherapy	Phase II trials from GMALL, NILG, PETHEMA, CALGB, NCI; single phase III trial from GRAALL/Lysa
BCP ALL (Ph-, Ph+)	Frontline therapy	Rituximab/ ofatumomab (CD20) plus chemotherapy	Phase II trials in Ph- CD20+ ALL (MDACC, GMALL) Ongoing phase III trials in Ph- CD20+ and CD20- ALL (GRAALL, MRC UK)
BCP ALL (Ph-, Ph+)	Frontline therapy	Inotuzumab ozogamicin (CD22) plus chemotherapy	Phase II trial in elderly Ph- ALL (MDACC)
BCP ALL (Ph-, Ph+)	Frontline therapy	Blinatumomab (CD19) plus chemotherapy	Ongoing phase III trial in Ph- ALL (ECOG)
	MRD+ (CR1)	Blinatumomab (CD19), single agent	Pilot phase II trial (GMALL), confirmatory phase II trial (International)